Baxter International Aktie
WKN: 853815 / ISIN: US0718131099
27.10.2015 12:40:03
|
Baxter International Q3 Profit Declines; Sees Lower Sales In Q4
(RTTNews) - Baxter International Inc. (BAX) on Tuesday reported a sharp decline in profit for the third quarter from last year on lower sales and one-time charges related to the spin-off of Baxalta Inc.
Net income for the third quarter was $1 million or breakeven per share, down from $468 million or $0.54 per share in the year-ago period.
Excluding items, adjusted earnings per share from continuing operations were $0.41, compared to $0.44 per share last year. On average, analysts polled by Thomson Reuters expected the company to report profit per share of $0.29 for the quarter. Analysts' estimates typically exclude special items.
Worldwide net sales for the quarter declined 8 percent to $2.49 billion from $2.71 billion last year, driven by a negative impact from foreign exchange. Analysts had a consensus revenue estimate of $2.46 billion.
Excluding the impact of foreign exchange, Baxter's worldwide sales grew 2 percent in the quarter and exceeded the company's guidance of comparable year-over-year sales.
Looking ahead to the fourth quarter, Baxter expects sales to decline 1 percent, excluding the impact of foreign exchange. On a reported basis, including the impact of foreign exchange, the company expects sales to decline about 9 percent.
After adjusting for the impact of both foreign exchange and increased competition in the U.S. for cyclophosphamide, Baxter expects sales growth of 1 to 2 percent in the fourth quarter of 2015.
Baxter also expects earnings from continuing operations, before special items, of $0.30 to $0.32 per diluted share for the fourth quarter, The Street expects the company to earn $0.30 per share for the quarter on revenues of $2.55 billion.
For fiscal 2015, Baxter expects sales to increase about 1 percent excluding the impact of foreign exchange. After adjusting for the impact of both foreign exchange and increased U.S. competition for cyclophosphamide, the company expects full-year sales growth of about 3 percent.
For the second half of 2015, the company now expects earnings from continuing operations, before special items, of $0.71 to $0.73 per share, up from its previous earnings guidance of $0.58 to $0.62 per share.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Baxter International Inc.mehr Nachrichten
Analysen zu Baxter International Inc.mehr Analysen
Aktien in diesem Artikel
Baxter International Inc. | 27,50 | -1,56% |
|